Key statistics dashboard for ProPhase Labs, Inc. (PRPH). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services.
Stock Data
| Price | $0.01 |
| Market Cap | $0M |
| Enterprise Value | $9.3M |
| Exchange | OTC |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.01 |
| Price / Book | -0.09 |
| P/S | 0.09 |
| EV/EBITDA | -1.30 |
| EV/Sales | 2.95 |
| EV/FCF | -0.30 |
| P/FCF | -0.01 |
| Earnings Yield | -11473.29% |
| FCF Yield | -15549.12% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 16.38% |
| EBIT Margin | -481.08% |
| EBITDA Margin | -226.49% |
| Operating Margin | -498.73% |
| Net Margin | -717.43% |
| Return on Equity | -1358.66% |
| Return on Assets | -39.44% |
| Return on Invested Capital | -188.35% |
| Return on Capital Employed | 2321.53% |
Financial Health
| Current Ratio | 0.05 |
| Quick Ratio | 0.05 |
| Cash Ratio | 0.00 |
| Debt / Equity | -2.93 |
| Debt / Assets | 15.89% |
| Net Debt / EBITDA | -1.27 |
| Interest Coverage | -2.17 |
Per-Share Data
| Revenue per share | 0.23 |
| Book Value per share | -0.22 |
| Cash per share | 0.00 |
| FCF per share | -2.19 |
| Tangible Book Value per share | -0.92 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 0.50 |
Related companies: ADAP · AEMD · ALUR · AYTU · BFRI · CODX · ERNA
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of PRPH: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks